Cargando…
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer
The development of trastuzumab (Herceptin(®)) was one of the most significant cancer drug development projects of the 20th century. Not only was it a scientific and medical achievement but it also paved the way for the drug-diagnostic codevelopment model, where a predictive biomarker assay is develo...
Autores principales: | Jørgensen, Jan Trøst, Winther, Henrik, Askaa, Jon, Andresen, Lena, Olsen, Dana, Mollerup, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343532/ https://www.ncbi.nlm.nih.gov/pubmed/34367962 http://dx.doi.org/10.3389/fonc.2021.676939 |
Ejemplares similares
-
Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects
por: Olsen, Dana, et al.
Publicado: (2014) -
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022) -
The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021) -
Drug-Diagnostics Co-Development in Oncology
por: Jørgensen, Jan Trøst
Publicado: (2014) -
The Different Roles of MET in the Development and Treatment of Cancer
por: Mollerup, Jens, et al.
Publicado: (2023)